1 Introduction Bladder cancer (BLCA) was the fourth most common cancer among men in 2023, accounting for 6% of estimated new cancers and 4% of cancer-related deaths [1]. Although 70%–80% of patients are initially diagnosed with non-muscle-invasive BLCA (NMIBC), within 5 years, 31%–78% will experience a relapse, and 10%–15% will progress to muscle-invasive BLCA (MIBC), resulting in a reduced 5-year survival rate of 36%–48% [2].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jinbang
Contact Jinbang, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack